Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults

Aim. The practical guidelines are intended for primary care physicians, general practitioners, paediatricians, gastroenterologists and general internists to advance the treatment and prevention of gastroenterological diseases in adults and children in therapies with probiotics, prebiotics, synbiotics and their enriched functional foods.

Key points. Probiotics are live microorganisms that sustain health of the host when supplied in adequate amounts. Prebiotics include human-indigestible but accessible to gut microbiota substances expediting specific changes in the composition and/or activity of gastrointestinal microbiota that favour the host health. The mechanism of probiotic action comprises the quorum resistance maintenance, nutrient substrate metabolism and end metabolite recycling, macroorganism-sustaining substrate production, as well as the mediation of local and adaptive immune responses.

The Russian Federation regulates market differently for biologically active food additives (BAFA), medicinal products (drugs) and functional food products (FFP). We overview the probiotic strains regulated in Russia as BAFAs, drugs and FFPs and provide recommendations on the use of these strains in treatment and prevention of gastroenterological diseases in children and adults.

Conclusion. The clinical efficacy of probiotics, prebiotics, synbiotics and fortified functional foods depends on the prebiotic and strain properties and is verified in appropriate comparative clinical trials. Not all probiotics registered in Russia as BAFAs, drugs and FFPs have a strain identity, which provides no warranty of the clinical effect expected. The FFP legislation demands improved regulation mechanisms and control for therapeutic efficacy.

1. World Gastroenterology Organisation. Probiotics and prebiotics. 2017. https://www.worldgastroenterology.org/guidelines

2. Markowiak P., Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017;9(9):1021. DOI: 10.3390/nu9091021

3. Davani-Davari D., Negahdaripour M., Karimzadeh M., Seifan M., Mohkam M., Masoumi S. J., et al. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods. 2019;8(3):92. DOI: 10.3390/foods8030092

4. Pandey K.R., Naik S.R., Vakil B.V. Probiotics, prebiotics and synbiotics — a review. J Food Sci Technol. 2015;52(12):7577–87. DOI: 10.1007/s13197-015-1921-1

5. Plaza-Diaz J., Ruiz-Ojeda F.J., Gil-Campos M., Gil A. MechanismsofActionofProbiotics.AdvNutr.2019;10(Suppl1): S49–66. DOI: 10.1093/advances/nmy063

6. Halloran K., Underwood M.A. Probiotic mechanisms of action. Early Hum Dev. 2019;135: 58–65. DOI: 10.1016/j.earlhumdev.2019.05.010

7. Canfora E.E., Jocken J.W., Blaak E.E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol.2015;11(10):577–91. DOI: 10.1038/nrendo.2015.128

8. Strandwitza P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693(Pt B):128–33. DOI: 10.1016/j.brainres.2018.03.015

9. de Moreno de LeBlanc A., Levit R., de Giori G.S., LeB-lanc J.G. Vitamin Producing Lactic Acid Bacteria as Complementary Treatments for Intestinal Inflammation. Antiinflamm Antiallergy Agents Med Chem. 2018;17(1):50–6. DOI: 10.2174/1871523017666180502170659

10. Halloran K., Underwood M.A. Probiotic mechanisms of action. Early Hum Dev. 2019; 135:58–65. DOI: 10.1016/j.earlhumdev.2019.05.010.

11. Scott K.P., Gratz S.W., Sheridan P.O., Flint H.J., Duncan S.H. The influence of diet on the gut microbiota. Pharmacol. Res. 2013; 69:52–60. DOI: 10.1016/j.phrs.2012.10.020

12. Ze X., Duncan S.H., Louis P., Flint H.J. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J. 2012; 6:1535–43. DOI: 10.1038/ismej.2012.4

13. GOST R 52349-2005 Food products. Functional food products. Terms and definitions (with Amendment No. 1). Date of effect 2006-07-01 http://docs.cntd.ru/document/1200039951

14. Eurasian Economic Commission. Unified Sanitary, Epidemiological and Hygienic Requirements for Products(Goods) Subject to Sanitary and Epidemiological Surveillance (Control), as amended on 10 May,2018(Revision effective from 1 June, 2019) http://www.eurasiancommission.org/ru/act/texnreg/depsanmer/sanmeri/Pages/P2_299.aspx http://www.eurasiancommission.org/ru/act/texnreg/depsanmer/sanmeri/Pages/P2_299.aspx

15. Federal Service on Customers’ Rights Protection and Human Wellbeing Surveillance. What one needs to know about dietary supplements. Information Bulletin of 12.05.2019. https://www.rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=11900 https://www.rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=11900

16. TR CU 021/2011 Technical Regulation of the Customs Union “On Food Safety” of 9 December,2011, No. 880 (as amended on 8 August, 2019) http://old.gost.ru/wps/portal/pages/main http://old.gost.ru/wps/portal/pages/main

17. Decree of the Chief Public Health Officer of the Russian Federation of February 18, 2008, No. 13 “On Approval of SanPiN 2.3.2.2340-08”. Registered by the Ministry of Justice of Russia on March11, 2008. Registered No. 11311(In Russ.) https://rg.ru/2010/12/30/sanpin-site-dok.html.

18. Federal Law of the Russian Federation of 12 April, 2010, No. 61-FZ «On Regulation of Drugs» (In Russ.) https://rg.ru/2010/04/14/lekarstva-dok.html

19. Order of the Ministry of Health of the Russian Federation No. 403n of 11 July, 2017, “On Approval of Rules for Dispensing Drugs for Medical Use, Including Immunobiological Drugs, by Pharmaceutical Organisations and Individual Entrepreneurs Licensed to Conduct Pharmaceutical Activities” of 12 September, 2017(In Russ.) https://rg.ru/2017/09/12/minzdrav-prikaz403-sitedok.html

20. General Pharmacopoeial Article “Probiotics” OFS.1.7.1.0008.15 of the Ministry of Health of the Russian Federation (In Russ.) http://femb.ru/femb/pharmacopea.php

21. Federal Law «On Quality and Safety of Foodstuffs» of 02.01.2000, No.29-FZ(In Russ.) URL: https://rg.ru/2000/01/02/produkty-dok.html.

22. Federal Law No. 47-FZof 01.03.2020“OnAmendments to the Federal Law ‘On Quality and Safety of Foodstuffs’ and Article 37 of the Federal Law ‘On Education in the Russian Federation’” (In Russ.) URL: https://rg.ru/2020/03/03/pitanie-dok.html.

23. GOST P 55577-2013. National Standard of the Russian Federation. Specialised and functional food products. Information on distinguishing characters and efficacy (In Russ.) URL: https://internet-law.ru/gosts/gost/55874/

24. GOST R 54059-2010. National Standard of the Russian Federation. Functional food products. Functional food ingredients. Classification and general requirements (In Russ.) URL:https://internet-law.ru/gosts/gost/50895/

25. Shi L.H., Balakrishnan K., Thiagarajah K., Mohd Ismail N.I., Yin O.S. Beneficial Properties of Probiotics. Trop Life Sci Res. 2016;27(2):73–90. DOI: 10.21315/tlsr2016.27.2.6

26. Ishibashi N., Yamazaki S. Probiotics and safety. Am J Clin Nutr. 2001;73(2 Suppl):465S–470. DOI: 10.1093/ajcn/73.2.465s

27. de Vos P., Faas M.M., Spasojevic M.M., Sikkema J. Encapsulation for preservation of functionality and targeted delivery of bioactive food components. Int Dairy J. 2010; 20:292–302. DOI: 10.1016/j.idairyj.2009.11.008

28. Burgain J., Gaiani C., Linder M., Scher J. Encapsulation of probiotic living cells: from laboratory scale to industrial applications. J Food Eng. 2011; 104:467–83. DOI: 10.1016/j.jfoodeng.2010.12.031

29. Salas-Jara M., Ilabaca A., Vega M., García A. Biofilm forming Lactobacillus: new challenges for the development of probiotics. Microorganisms. 2016;4(3):35. DOI: 10.3390/microorganisms4030035

30. Tsai Y.L., Lin T.L., Chang C.J., Wu T.R., Lai W.F., Lu C.C., Lai H.C. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019;26(1):3. DOI: 10.1186/s12929-018-0493-6

31. Howick J., Chalmers I., Glasziou P., Greenhalgh T., Heneghan C., Liberati A., et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). OxfordCentre for Evidence-Based Medicine. https://www.cebm.net/index.aspx?o=5653

32. Allen S.J., Martinez E.G., Gregorio G.V., Dans L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;(11):CD003048. DOI: 10.1002/14651858.CD003048.pub3

33. Höchter W., Hagenhoff G. Saccharomyces boulardii in acute adult diarrhea: efficacy and tolerability of treatment. Munch Med Wochenschr. 1990;(132):188–92.

34. Grossi E., Buresta R., Abbiati R., Cerutti R., Pro-DIA study group.Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with acute diarrhea: a multicenter, randomized study in primary care. J Clin Gastroenterol. 2010;44 Suppl 1: S35–41. DOI: 10.1097/MCG.0b013e3181e103f4

35. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N.V., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959–69. DOI: 10.1001/jama.2012.3507

36. Ouwehand A.C., Dong-Lian C., Weijian X., Stewart M., Ni J., Stewart T., et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose responsestudy. Vaccine. 2014;32(4):458–63

37. Chatterjee S., Kar P., Das T., Ray S., Gangulyt S., Rajendiran C., et al. Randomised placebocontrolled double blind multicenteric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India. 2013;61(10):708–12.

38. Hickson M., D’Souza A.L., Muthu N., Rogers T.R., Want S., Rajkumar C., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomized double blind placebo controlledtrial.BMJ. 2007;335(7610):80. DOI:10.1136/bmj.39231.599815.55

39. Cimperman L., Bayless G., Best K., Diligente A., Mordarski B., Oster M., et al. Arandomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrheain hospitalized adults. J Clin Gastroenterol. 2011;45(9):785–9. DOI: 10.1097/MCG.0b013e3182166a42

40. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095. DOI: 10.1002/14651858.CD006095.pub4

41. Lewis S., Burmeister S., Brazier J.Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol. 2005;3(5):442–8. DOI: 10.1016/s1542-3565(04)00677-9

42. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori. A network meta-analysis Medicine (Baltimore). 2019;98(15): e15180. DOI: 10.1097/MD.0000000000015180

43. Dang Y., Reinhardt J.D., Zhou X., Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication the rapy: a meta-analysis. PloS One. 2014;9(11): e111030. DOI: 10.1371/journal.pone.0111030

44. Ojetti V., Bruno G., Ainora M.E., Gigante G., Rizzo G., Roccarina D., et al. Impactof Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterol Res Pract. 2012; 2012:740381. DOI: 10.1155/2012/740381

45. Li I.A., Silvestrova S.Yu., Drozdov V.N. “Rioflora Balans Neo” probiotic and anti-Helicobacter therapy: increased efficacy at reduced adverse events. Medical Council. 2013;(10):100–3 (In Russ.). DOI: 10.21518/2079-701X-2013-10-100-103

46. Ducrotté P., Sawant P., Jayanthi V.Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012–8. DOI: 10.3748/wjg.v18.i30.4012

47. Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndromeand chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–61; quiz 1546, 1562. DOI: 10.1038/ajg.2014.202

48. Choi C.H., Jo S.Y., Park H.J., Chang S.K., Byeon J.S., Myung S.J. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011;45(8):679–83. DOI: 10.1097/MCG.0b013e318204593e

49. Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O’Mahony L., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–90. DOI: 10.1111/j.1572-0241.2006.00734.x

50. Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx-Orenstein A.E., Brandt L.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325–32. DOI: 10.1136/gut.2008.167270

51. Lorenzo-Zúñiga V., Llop E., Suárez C., Álvarez B., Abreu L., Espadaler J., et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709–16. DOI: 10.3748/wjg.v20.i26.8709

52. Ivashkin V., Drapkina O., Poluektova Ye., Kuchumova S., Sheptulin A., Shifrin O. The Effect of a Multistrain Probiotic on the Symptoms and Small Intestinal Bacterial Overgrowth in Constipation-predominant Irritable Bowel Syndrome: A Randomized, Simple-blind, Placebo-controlled Trial. American Journal of Clinical Medicine Research. 2015;3(2):18–23. DOI: 10.12691/ajcmr-3-2-1

53. Guyonnet D., Schlumberger A., Mhamdi L., Jakob S., Chassany O. Fermented milk containing Bifidobacterium lactis DN-173 010improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomized, double-blind, parallel, controlled study. British Journal of Nutrition, 2009;102(11):1654–62. DOI: 10.1111/j.1365-2036.2007.03362.x

54. Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch Iran Med. 2014;17(7):466–70. DOI: 0141707/AIM.003

55. Yang Y.X., He M., Hu G., Wei J., Pages P., Yang X.H., et al. Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol. 2008;14(40):6237–43. DOI: 10.3748/wjg.14.6237

56. Ojetti V., Ianiro G., Tortora A., D’Angelo G., Di Rienzo T.A., Bibbò S., et al. Theeffect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointest Liver Dis JGLD. 2014;23(4):387–91. DOI: 10.15403/jgld.2014.1121.234.elr

57. Schumann C. Medical,nutritional and technologicalproperties of lactulose. An update. Eur J Nutr. 2002;41 Suppl 1: I17–25. DOI: 10.1007/s00394-002-1103-6

58. Nyman M. Fermentation and bulkingcapacity of indigestible carbohydrates: the case of inulin and oligofructose. Br J Nutr. 2002;87 Suppl 2: S163–8. DOI: 10.1079/BJNBJN/2002533

59. Eales J., Gibson P.R., Whorwell P.J., Kellow J., Yellowlees A., Perry R., et al. Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population. Therap Adv Gastroenterol. 2017;10(1):74–88. DOI: 10.1177/1756283X16670075

60. Gluud L.L., Vilstrup H., Morgan M.Y. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol fortheprevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane DatabaseSystRev.2016;4: CD003044. DOI: 10.1002/14651858.CD003044.pub3

61. Szajewska H., Guarino A., Hojsak I., Indrio F., Kolacek S., Shamir R., et al.; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014;58(4):531–9. DOI: 10.1097/MPG.0000000000000320

62. Szajewska H., Skórka A., Ruszczyński M., Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 2013;38(5):467–76. DOI: 10.1111/apt.12403

63. Szajewska H., Skórka A. Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther. 2009;30(9):960–1. DOI: 10.1111/j.1365-2036.2009.04113.x

64. Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149–57. DOI: 10.1111/apt.13404

65. Pedone C.A., Arnaud C.C., Postaire E.R., Bouley C.F., Reinert P. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract. 2000;54(9):568–71.

66. Agustina R., Kok F.J., van de Rest O., Fahmida U., Firmansyah A., Lukito W., et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012;129(5):e1155–64. DOI: 10.1542/peds.2011-1379

67. Gutierrez-Castrellon P., Lopez-Velazquez G., Diaz-Garcia L., Jimenez-Gutierrez C., Mancilla-Ramirez J., Estevez-Jimenez J., et al. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics. 2014;133(4): e904–9. DOI: 10.1542/peds.2013-0652

68. Szajewska H., Horvath A., Kołodziej M.Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pyloriinfection. Aliment Pharmacol Ther. 2015;41(12):1237–45. DOI: 10.1111/apt.13214

69. Sykora J., Valeckova K., Amlerova J., Siala K., Dedek P., Watkins S., et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus caseiDN-114 001 and the eradication of H. pylori in children: a prospective randomised double-blind study. J Clin Gastroenterol. 2005;39(8):692–8. DOI: 10.1097/01.mcg.0000173855.77191.44

70. Urbańska M., Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children:a review of the current evidence. Eur J Pediatr. 2014;173(10):1327–37. DOI: 10.1007/s00431-014-2328-0

71. Horvath A., Dziechciarz P., Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33(12):1302–10. DOI: 10.1111/j.1365-2036.2011.04665.x